Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.
For many cancer types, women have lower incidence and better outcomes than men. The role of sex steroid hormones, such as estrogen and testosterone, has been studied in reproductive organ cancers such as prostate and breast cancer, but not in other non-androgen (AR)-driven cancers. Recent studies have shown that testosterone promotes cancer cell proliferation.
Inhibiting testosterone-induced tumor growth as a new therapeutic approach for non-AR-driven cancer.
Dr. Ridky and colleagues demonstrated that testosterone promotes cancer cell proliferation through a non-AR-dependent mechanism. Four existing FDA-approved androgen receptor inhibitors, flutamide, bicalutamide, enzalutamide, and apalutamide, are inhibiting the proliferation of different cancer cell lines, from non-reproductive non-AR expressing tissues. Hence these therapeutics may have a way broader therapeutic effect than earlier contemplated.
Both bicalutamide (CDX) and enzalutamide (ENZ) completely block testosterone-induced proliferation of melanoma cell lines.
Tumor growth in SCID male mice bearing WM46-derived subcutaneous tumors was inhibited by Apalutamide (20mg/kg/day via oral gavage).
Enhance effectiveness of current cancer therapy treatment using already approved drugs
Stage of Development:
In Vivo POC
Patent application filed
Sponsored research and licensing
Docket # 20-9153